News

MAF Test validation in a second retrospectively analyzed prospectively randomized clinical trial (NSABP B34) data were presented at ASCO 20

The co-founder of Inbiomotion (Dr. Roger Gomis) and part of the team have published the results that validated MAF test ability to identify breast cancer patients that benefit from the use of bisphosphonate in adjuvancy in a second retrospective analysis of a prospective randomized clinical trial; NSABP-B34 (NCT00009945). (Paterson et al., J Clin Oncology, 2020; doi: 10.1200/JCO.2020.38.15_suppl.513). The results were presented at the ASCO meeting 2020 (Abstract #513).

Read More about "MAF Test validation in a second retrospectively analyzed prospectively randomized clinical trial (NSABP B34) data were presented at ASCO 20"

Inbiomotion announces approval of NSABP B34 validation study by National Cancer Institute (NCI) and the NRG groups

Barcelona, Spain, 2018 - Inbiomotion S.L., a biotech company specialized in the development of companion diagnostics for the use of bone modifying agents, has just announced that has been granted of access to the NSABP B34 trial by the National Cancer Institute and NRG Oncology Group, US, to validate its proprietary biomarker.

Read More about "Inbiomotion announces approval of NSABP B34 validation study by National Cancer Institute (NCI) and the NRG groups"

Long term follow-up of Phase 3 AZURE prospective/retrospective study of MAFTest® in Journal of Bone Oncology demonstrates the survival benefit effect of MAF gene amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer

Inbiomotion SL today announced the publication of the results of the long-term follow-up of Phase 3 AZURE prospective/retrospective analysis using its proprietary single gene based MAFTest® in the September issue of Journal of Bone Oncology.

Read More about "Long term follow-up of Phase 3 AZURE prospective/retrospective study of MAFTest® in Journal of Bone Oncology demonstrates the survival benefit effect of MAF gene amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer"

Phase 3 prospective/retrospective study of MAFTest® in Lancet Oncology demonstrates the effect of MAF gene amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer

Inbiomotion SL today announced the publication of the results of the Phase 3 AZURE prospective/retrospective analysis using its proprietary single gene based MAFTest® in the November issue of Lancet Oncology

Read More about "Phase 3 prospective/retrospective study of MAFTest® in Lancet Oncology demonstrates the effect of MAF gene amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer"

”la Caixa” leads an investment round in Inbiomotion with the participation of Ysios Capital

The investment has been made through Caixa Innvierte BioMed II, a vehicle managed by Caixa Capital Risc, the venture capital arm of "la Caixa". The fund is driven by "la Caixa" and the Centro para el Desarrollo Tecnológico Industrial (Centre for Industrial Technological Development, CDTI) under the framework of the Innvierte Programme and has minority participation from the Institut Català de Finances.

Read More about "”la Caixa” leads an investment round in Inbiomotion with the participation of Ysios Capital"

IRB Barcelona identifies the gene responsible for metastasis of breast cancer to the bone

Physicians currently have no tools to help them detect which breast cancer patients will suffer metastasis to the bone, a process that occurs in 15-20% of cases. A study led by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) and published today in JNCI has uncovered a gene that allows breast cancer cells to invade bones and create new tumours, or to metastasize.

Read More about "IRB Barcelona identifies the gene responsible for metastasis of breast cancer to the bone"

Inbiomotion creates a world class Scientific Advisory Board chaired by Prof. Rob E. Coleman

Inbiomotion SL, a company focused on the development of biomarkers for the prediction of bone metastasis, today announced the creation of its Scientific Advisory Board with renowned experts in various disciplines, including bone metastatic disease, biomarker development, translational research and medical oncology.

Read More about "Inbiomotion creates a world class Scientific Advisory Board chaired by Prof. Rob E. Coleman"